Herceptin is a monoclonal antibody that specifically targets human epidermal growth factor receptor 2 (HER2) and is currently an FDA approved therapy for the treatment of early and late stage breast cancer patients with HER2 overexpression (176). Here, ERBB2 is linked to breast carcinoma.